Montelukast Sodium Market: By Dosage Form (Tablets, Oral Solutions, Simple Pills, Chewable Pills, Powder, and Others), By Indication (Asthma, Allergic Rhinitis, Urticaria, and Others), By Product (Crystal-like and Form-less/Amorphous), and By Geography (North America, Europe, Asia Pacific, Latin America, and MEA), and Forecast to 2030.

Purchase Option

$ 4400
$ 6600
$ 8900

The global montelukast sodium market was valued at USD 4,373.6 million in 2023 and is estimated to grow at 6.1% CAGR from 2024 to 2030. The montelukast sodium is a medication primarily used for the treatment of asthma and allergic rhinitis. It belongs to a class of drugs known as leukotriene receptor antagonists, which work by blocking the action of leukotrienes, substances in the body that contribute to inflammation, bronchoconstriction and other symptoms associated with asthma and allergies. The market for montelukast sodium includes both brand-name and generic versions of the medication, with various pharmaceutical companies producing and distributing it worldwide. In April 2022, scientists at the Indian Institute of Science in Bengaluru conducted a study that revealed that montelukast has the potential to stop COVID variants from replicating within the body of the infected. Thus, the studied market has been significantly impacted by the COVID-19 pandemic. Moreover, the latest research on new montelukast treatment approaches is expected to drive the market in the coming years. The major factor attributing to the growth of the market is the increasing prevalence of diseases like asthma, allergic rhinitis, exercise-induced bronchospasm, primary dysmenorrhea, and urticaria. and rise in the geriatric population. Furthermore, in 2021, the Asthma and Allergy Foundation of America (AAFA) reported that each year, anaphylaxis (a severe allergic reaction) to food results in 90,000 emergency room visits, and more than 50 million people in the United States experience various types of allergies. However, side effects with the product, such as stomach pain, heartburn, upset stomach, nausea, and diarrhoea may turn patients aversive toward consumption of montelukast and can cripple its overall market. Additionally, regulatory agencies have issued warnings and required updated labelling to reflect these safety concerns. Addressing these safety issues, conducting further research to understand the risks better, and implementing risk mitigation strategies present challenges for manufacturers in maintaining consumer confidence and regulatory compliance while ensuring the continued availability of montelukast sodium in the market.

Recent Developments of the Market:

  • In March 2021, Valeo Pharma Inc. entered into a commercialization and supply agreement with Novartis Pharmaceuticals Canada Inc. for the Canadian commercialization by Valeo of two asthma therapies, Enerzair Breezhaler, glycopyrronium, and mometasone furoate and Atectura Breezhaler.
  • In May 2021, montelukast Sodium was included in the Health Choice Arizona Formulary / Preferred Drug List. A Formulary / Preferred Drug List (PDL) is a list of drugs chosen by Health Choice Arizona and a team of doctors and pharmacists. Health Choice will cover the drugs listed in our PDL as long as they are medically necessary and appropriate. All Health Choice member prescriptions must be filled at a Health Choice Arizona network pharmacy, and other plan rules must be followed.

Montelukast Sodium Market Summary

Study Period

2024 - 2030

Base Year

2023

CAGR

6.1%

Largest Market

North America

Fastest Growing Market

Asia pacific
Montelukast Sodium Market Dynamics

The growing geriatric population is projected to drive the market growth of montelukast sodium. The world population is growing at a steady pace especially in Asian nations like India and China as both nations contribute around 36% to the total world population. Out of 7.9 billion people, around 4.6 billion people live in Asia. Along with the overall shoot-up in population old-age faction is also elevating. There are around 700 million people aged above 65 and the number is expected to enlarge up to 1-2 billion in the coming future. Old age carries corporeal misery and is more prone to respiratory problems. Additionally, the pollution problem is increasing around the globe due to rapid industrialization. Overuse of coal to produce electricity and several production processes is increasing the carbon content in the environment and resulting in rising temperatures. On the other hand, due to rising disposable income people’s purchasing power is on the rise. As a result, they are making automobile purchases. All these factors increase pollution, which results in health complications like asthma, and allergic coryza. As per WHO, an air quality above >101 can result in asthma and other bronchial problems in susceptible patients. Following this, countries such as India and China have been a forefront leader in terms of high AQI, which will allow for market growth.

Montelukast Sodium Market Segmentation

By Dosage
  • Tablets
  • Oral Solutions
  • Simple Pills
  • Chewable Pills
  • Powder
  • Others
By Indication
  • Asthma
  • Allergic Rhinitis
  • Urticaria
  • Others
By Product
  • Crystal-like
  • Form-less/Amorphous

Frequently Asked Questions

The global montelukast sodium market was valued at USD 4,373.6 million in 2023 and is estimated to grow at 6.1% CAGR from 2024 to 2030.

The leading players in the montelukast sodium market are Merck & Co. Inc., Morepen Laboratories, Teva Pharmaceuticals USA Inc., Sanofi Aventis SA, Cipla Limited, Intas Pharmaceuticals Ltd., SUN PHARMA, SK Capital (Apotex Inc.), Hetero Labs, Ortin laboratories, Mylan N.V, MSN Laboratories, Vamsi Labs, and Medopharm.

Rising prevalence of respiratory diseases & growing awareness and adoption of asthma management therapies are the growth drivers of the montelukast sodium market.

Dosage form and application are the key segments covered in the montelukast sodium market research.

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030).
  • The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies.
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market.
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market.
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario.

 

1. Executive Summary
2. Global Montelukast Sodium Market Introduction 
2.1.Global Montelukast Sodium Market  - Taxonomy
2.2.Global Montelukast Sodium Market  - Definitions
2.2.1.Dosage
2.2.2.Indication
2.2.3.Product
2.2.4.Region
3. Global Montelukast Sodium Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.6. New Product Launches
3.7. Impact of COVID 19 on Market
4. Global Montelukast Sodium Market Analysis, 2019 - 2023 and Forecast 2024 - 2030
4.1.  Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
4.2.  Year-Over-Year (Y-o-Y) Growth Analysis (%) 
4.3.  Market Opportunity Analysis 
5.Global Montelukast Sodium Market  By Dosage, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
5.1. Tablets
5.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.1.3. Market Opportunity Analysis 
5.2. Oral Solutions
5.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.2.3. Market Opportunity Analysis 
5.3. Simple Pills
5.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.3.3. Market Opportunity Analysis 
5.4. Chewable Pills
5.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.4.3. Market Opportunity Analysis 
5.5. Powder
5.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.5.3. Market Opportunity Analysis 
5.6. Others
5.6.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
5.6.3. Market Opportunity Analysis 
6.Global Montelukast Sodium Market  By Indication, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
6.1. Asthma
6.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.1.3. Market Opportunity Analysis 
6.2. Allergic Rhinitis
6.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.2.3. Market Opportunity Analysis 
6.3. Urticaria
6.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.3.3. Market Opportunity Analysis 
6.4. Others
6.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
6.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
6.4.3. Market Opportunity Analysis 
7.Global Montelukast Sodium Market  By Product, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
7.1. Crystal-like
7.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.1.3. Market Opportunity Analysis 
7.2. Form-less/Amorphous
7.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
7.2.3. Market Opportunity Analysis 
8.Global Montelukast Sodium Market  By Region, 2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.1.3. Market Opportunity Analysis 
8.2. Europe
8.2.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.2.3. Market Opportunity Analysis 
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.3.3. Market Opportunity Analysis 
8.4. Middle East and Africa (MEA)
8.4.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.4.3. Market Opportunity Analysis 
8.5. Latin America
8.5.1. Market Analysis, 2019 - 2023 and Forecast, 2024 - 2030, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) 
8.5.3. Market Opportunity Analysis 
9.North America Montelukast Sodium Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
9.1. Dosage Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.1.1.Tablets
9.1.2.Oral Solutions
9.1.3.Simple Pills
9.1.4.Chewable Pills
9.1.5.Powder
9.1.6.Others
9.2.  Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.2.1.Asthma
9.2.2.Allergic Rhinitis
9.2.3.Urticaria
9.2.4.Others
9.3.  Product Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.3.1.Crystal-like
9.3.2.Form-less/Amorphous
9.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
9.4.1.United States of America (USA)
9.4.2.Canada
10.Europe Montelukast Sodium Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
10.1. Dosage Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.1.1.Tablets
10.1.2.Oral Solutions
10.1.3.Simple Pills
10.1.4.Chewable Pills
10.1.5.Powder
10.1.6.Others
10.2.  Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.2.1.Asthma
10.2.2.Allergic Rhinitis
10.2.3.Urticaria
10.2.4.Others
10.3.  Product Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.3.1.Crystal-like
10.3.2.Form-less/Amorphous
10.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
10.4.6.Rest of EU
11.Asia Pacific (APAC) Montelukast Sodium Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
11.1. Dosage Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.1.1.Tablets
11.1.2.Oral Solutions
11.1.3.Simple Pills
11.1.4.Chewable Pills
11.1.5.Powder
11.1.6.Others
11.2.  Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.2.1.Asthma
11.2.2.Allergic Rhinitis
11.2.3.Urticaria
11.2.4.Others
11.3.  Product Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.3.1.Crystal-like
11.3.2.Form-less/Amorphous
11.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12.Middle East and Africa (MEA) Montelukast Sodium Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
12.1. Dosage Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.1.1.Tablets
12.1.2.Oral Solutions
12.1.3.Simple Pills
12.1.4.Chewable Pills
12.1.5.Powder
12.1.6.Others
12.2.  Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.2.1.Asthma
12.2.2.Allergic Rhinitis
12.2.3.Urticaria
12.2.4.Others
12.3.  Product Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.3.1.Crystal-like
12.3.2.Form-less/Amorphous
12.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
12.4.1.GCC Countries
12.4.2.South Africa
12.4.3.Rest of MEA
13.Latin America Montelukast Sodium Market ,2019 - 2023 and Forecast 2024 - 2030 (Sales Value USD Million)
13.1. Dosage Analysis  and Forecast  by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.1.1.Tablets
13.1.2.Oral Solutions
13.1.3.Simple Pills
13.1.4.Chewable Pills
13.1.5.Powder
13.1.6.Others
13.2.  Indication Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.2.1.Asthma
13.2.2.Allergic Rhinitis
13.2.3.Urticaria
13.2.4.Others
13.3.  Product Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.3.1.Crystal-like
13.3.2.Form-less/Amorphous
13.4.  Country Analysis 2019 - 2023 and Forecast 2024 - 2030 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) 
13.4.1.Brazil
13.4.2.Mexico
13.4.3.Rest of LA
14. Competition Landscape
14.1.  Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) 
14.2.1.Merck & Co. Inc.
14.2.2.Morepen Laboratories
14.2.3.Teva Pharmaceuticals USA Inc.
14.2.4.Sanofi Aventis SA
14.2.5.Cipla Limited
14.2.6.Intas Pharmaceuticals Ltd.
14.2.7.SUN PHARMA
14.2.8.SK Capital (Apotex Inc.)
14.2.9.Hetero Labs
14.2.10.Ortin laboratories
14.2.11.Mylan N.V
14.2.12.MSN Laboratories
14.2.13.Vamsi Labs
14.2.14.Medopharm
15. Research Methodology 
16. Appendix and Abbreviations 
  • Merck & Co. Inc.
  • Morepen Laboratories
  • Teva Pharmaceuticals USA Inc.
  • Sanofi Aventis SA
  • Cipla Limited
  • Intas Pharmaceuticals Ltd.
  • SUN PHARMA
  • SK Capital (Apotex Inc.)
  • Hetero Labs
  • Ortin laboratories
  • Mylan N.V
  • MSN Laboratories
  • Vamsi Labs
  • Medopharm

Adjacent Markets